Prescription medicine
Secukinumab Brand names: Cosentyx
Secukinumab (Cosentyx) is a prescription medicine with an FDA approval on record since 2015. No generic is listed; pharmacies paid $3,946.35 per mL (Cosentyx sensoready 300 mg dose/2 pens (150 mg/pen)) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the secukinumab FDA label on DailyMed (effective August 25, 2026, Novartis Pharmaceuticals Corporation); the BLA 125504 record on Drugs@FDA; every secukinumab label on DailyMed.
Highlights of the record
FDA label of August 25, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageCOSENTYX is a human interleukin-17A antagonist indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults and pediatric patients 6 years and older who are candidates for systemic therapy or phototherapy.
Forms and strengths
- 25 mg/ml
- 75 mg/.5ml
- 150 mg/ml
- 300 mg/2ml
Injection; injection (solution) (concentrate).
On the market
- Earliest approval on file
- January 21, 2015 Cosentyx, Novartis Pharms Corp; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $3,946.35 per mL Cosentyx sensoready 300 mg dose/2 pens (150 mg/pen)
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 160,421 through July 30, 2026
What is secukinumab used for?
From the label: indications and usageCOSENTYX is a human interleukin-17A antagonist indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults and pediatric patients 6 years and older who are candidates for systemic therapy or phototherapy. ( 1.1 ) active psoriatic arthritis (PsA) in adults and pediatric patients 2 years of age and older. ( 1.2 ) active ankylosing spondylitis (AS) in adults and pediatric patients 12 years of age and older. ( 1.3 ) active non-radiographic axial spondyloarthritis (nr-axSpA) in adults with objective signs of inflammation. ( 1.4 ) active enthesitis-related arthritis (ERA) in pediatric patients 4 years of age and older. […]
Conditions named in the indications of secukinumab's FDA labels, with every medicine labeled for each:
From other secukinumab labelsPsoriasis: Plaque Psoriasis COSENTYX ® is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults and pediatric patients 6 years and older who are candidates for systemic therapy or phototherapy.
FDA pharmacologic class: Interleukin-17A Antagonist.
Source: FDA drug label (COSENTYX), Novartis Pharmaceuticals Corporation, effective August 25, 2026 (SPL set 77c4b13e-7df3-42d4-81db-3d0cddb7f67a), via openFDA; the full label on DailyMed
What does the patient leaflet for secukinumab say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about COSENTYX?COSENTYX is a medicine that affects your immune system. COSENTYX may increase your risk of having serious side effects such as: Infections. COSENTYX may lower the ability of your immune system to fight infections and may increase your risk of infections. Some people have had serious infections during treatment with COSENTYX, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses. Some people have died from these infections. Your healthcare provider should check you for TB before starting treatment with COSENTYX. If your healthcare provider feels that you are at risk for TB, you may be treated with medicine for TB before you begin treatment with COSENTYX and during treatment with COSENTYX. Your healthcare provider should watch you closely for signs and symptoms of TB during treatment with COSENTYX. Do not use COSENTYX if you have an active TB infection. Before starting COSENTYX, tell your healthcare provider if you: are being treated for an infection have an infection that does not go away or that keeps coming back have TB or have been in close contact with someone with TB have or have had Hepatitis B think you have an infection or have symptoms of an infection such as: ◦ fever, sweats, or chills ◦ muscle aches ◦ cough ◦ shortness of breath ◦ blood in your phlegm ◦ weight loss ◦ warm, red, or painful skin or sores on your body ◦ diarrhea or stomach pain ◦ burning when you urinate or urinate more often than normal After starting COSENTYX, call your healthcare provider right away if you have any of the signs of infection listed above. Do not use COSENTYX if you have any signs of infection unless you are instructed to by your healthcare provider. See “What are the possible side effects of COSENTYX?” for more information about side effects.
From the patient leaflet: How should I store COSENTYX?Store COSENTYX in a refrigerator between 36°F to 46°F (2°C to 8°C). Keep COSENTYX in the original carton until ready for use to protect from light. If you use COSENTYX Sensoready pen or prefilled syringes (150 mg/mL, 75 mg/0.5 mL): It may be stored at room temperature, up to 86°F (30°C), for up to 4 days. Write the date it was removed from and returned to the refrigerator in the space provided on the carton. Throw it away if it has been stored outside of the refrigerator over 4 days. It may be returned to the refrigerator only 1 time and must be stored between 36°F to 46°F (2°C to 8°C) until you use it or until it expires. Do not freeze COSENTYX. Do not shake COSENTYX. Throw away any expired or unused COSENTYX. Keep COSENTYX and all medicines out of the reach of children.
Source: FDA drug label (COSENTYX), Novartis Pharmaceuticals Corporation, effective August 25, 2026 (SPL set 77c4b13e-7df3-42d4-81db-3d0cddb7f67a), via openFDA; the full label on DailyMed
Is there a generic for secukinumab (Cosentyx)?
No generic secukinumab is approved (Drugs@FDA, October 8, 2026).
- 2015 earliest approval on file
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for secukinumab (Cosentyx)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $3,946.35 per mL (Cosentyx sensoready 300 mg dose/2 pens (150 mg/pen)), up 7% from $3,691.40 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Cosentyx (150 mg/mL) 300 mg dose-2 syringes (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Cosentyx (150 mg/mL) 300 mg dose-2 syringes | Brand | $3,924.35 per mL | n/a | +6% |
| Cosentyx 150 mg/mL syringe | Brand | $7,879.81 per mL | n/a | +7% |
| Cosentyx sensoready 150 mg/mL pen | Brand | $7,858.48 per mL | n/a | +7% |
| Cosentyx sensoready 300 mg dose/2 pens (150 mg/pen) | Brand | $3,946.35 per mL | n/a | +7% |
| Cosentyx unoready 300 mg/2 mL pen (1 pen) | Brand | $4,087.41 per mL | $8,174.81 per pen | +6% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for secukinumab?
The FDA Adverse Event Reporting System holds 160,421 reports that list secukinumab among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 8,611 are coded as a death and 21,920 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as secukinumab?
7 other medicines are given the same way (subcutaneous) and in the same FDA class as secukinumab or labeled mainly for the same use (psoriasis), the same class first. Psoriasis lists all 38 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Ixekizumab | Psoriasis | none listed | $7,370.72 per mL 80 mg/mL autoinjector | No current entry |
| Adalimumab-ryvk | Psoriasis | none listed | $499.12 per unit 40 mg/0.4 mL autoinjector | A presentation being discontinued |
| Risankizumab | Psoriasis | none listed | $22,774.36 per mL 150 mg/mL pen | No current entry |
| Bimekizumab | Psoriasis | none listed | $8,073.83 per mL 160 mg/mL autoinjector | No current entry |
| Spesolimab | Psoriasis | none listed | n/a | No current entry |
| Brodalumab | Psoriasis | none listed | n/a | No current entry |
| Tildrakizumab | Psoriasis | none listed | n/a | No current entry |
Every medicine labeled for the same conditions as secukinumab
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to secukinumab
- 7 medicines for the same use
- Other interleukin-17a antagonists
- the pharmacologic class, with prices and generics
- Secukinumab side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other